California Doc's DEA Reg Revoked Over State License Issues
Published Date: 5/7/2025
Notice
Summary
Dr. Edmund Ayoub Jr. from California lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Ayoub
The DEA revoked Certificate of Registration No. FA0321036 for Edmund Ayoub Jr., M.D., meaning he may no longer prescribe, administer, dispense, or otherwise handle controlled substances. The revocation is effective June 6, 2025 and will directly affect his medical practice and any related income.
Pending DEA Applications Denied
The Order denies any pending applications of Edmund Ayoub Jr., M.D., to renew or modify Certificate of Registration No. FA0321036 and denies any other pending application for additional registration in California. This denial accompanies the revocation and prevents immediate restoration or expansion of DEA registration in California.
15-Day Reconsideration Window
The Order states that the registrant may file a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of the Order. Any such motion and response must be filed and served by email to the other party and to the DEA Office of the Administrator.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-07934, Margaret Dennis, D.M.D.; Default Decision and Order
Dr. Margaret Dennis from Jacksonville, FL, lost her DEA license because she prescribed controlled drugs without proper medical reasons and ignored warning signs for over 11 years. Since she didn’t ask for a hearing, her license is officially revoked to protect public safety. This means she can’t legally prescribe these drugs anymore, effective immediately.
Next: 2025-07936, Mohan Kaza, M.D.; Default Decision and Order
Dr. Mohan Kaza from Michigan had his DEA license suspended and is now losing it for giving out strong prescription drugs without proper exams or checks. He also coached undercover agents to lie and charged extra fees for higher doses. This decision protects public safety by stopping unsafe prescribing practices immediately.